Is BEAT or ICCM more profitable?

HeartBeam has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets HeartBeam N/A -686.78% -348.65% IceCure Medical -427.67% -174.26% -112.58%

Does the media refer more to BEAT or ICCM?

In the previous week, HeartBeam and HeartBeam both had 3 articles in the media. IceCure Medical's average media sentiment score of 0.91 beat HeartBeam's score of 0.86 indicating that IceCure Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ICCM or HSCS?

In the previous week, HeartSciences had 1 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for HeartSciences and 3 mentions for IceCure Medical. HeartSciences' average media sentiment score of 0.96 beat IceCure Medical's score of 0.91 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HeartSciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ICCM or FEMY more profitable?

IceCure Medical has a net margin of -427.67% compared to Femasys' net margin of -534.36%. IceCure Medical's return on equity of -174.26% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -427.67% -174.26% -112.58% Femasys -534.36% -225.97% -74.68%

Is ICCM or LFWD more profitable?

Lifeward has a net margin of -141.28% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets IceCure Medical -427.67% -174.26% -112.58% Lifeward -141.28% -235.86% -81.72%

Do analysts recommend MODD or ICCM?

IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 3,150.77%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Modular Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Modular Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

IceCure Medical (ICCM) Competitors

$1.62 +0.03 (+1.57%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$1.71 +0.10 (+6.07%)

As of 07:26 AM Eastern

Compare

ICCM vs. BEAT, HSCS, FEMY, LFWD, and MODD

Should you buy IceCure Medical stock or one of its competitors? IceCure Medical's main competitors and comparable companies include HeartBeam (BEAT), HeartSciences (HSCS), Femasys (FEMY), Lifeward (LFWD), and Modular Medical (MODD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does IceCure Medical compare to HeartBeam?

HeartBeam (NASDAQ:BEAT) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, HeartBeam and HeartBeam both had 3 articles in the media. IceCure Medical's average media sentiment score of 0.91 beat HeartBeam's score of 0.86 indicating that IceCure Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

HeartBeam has a beta of -0.8, suggesting that its share price is 180% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

HeartBeam presently has a consensus target price of $4.00, suggesting a potential upside of 991.11%. IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 3,150.77%. Given IceCure Medical's higher probable upside, analysts plainly believe IceCure Medical is more favorable than HeartBeam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

HeartBeam has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-686.78%	-348.65%
IceCure Medical	-427.67%	-174.26%	-112.58%

IceCure Medical has higher revenue and earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A
IceCure Medical	$3.38M	1.64	-$15.06M	-$8.52	N/A

Summary

IceCure Medical beats HeartBeam on 8 of the 15 factors compared between the two stocks.

How does IceCure Medical compare to HeartSciences?

IceCure Medical (NASDAQ:ICCM) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, HeartSciences had 1 more articles in the media than IceCure Medical. MarketBeat recorded 4 mentions for HeartSciences and 3 mentions for IceCure Medical. HeartSciences' average media sentiment score of 0.96 beat IceCure Medical's score of 0.91 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HeartSciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IceCure Medical has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

IceCure Medical presently has a consensus price target of $52.50, suggesting a potential upside of 3,150.77%. HeartSciences has a consensus price target of $8.00, suggesting a potential upside of 91.39%. Given IceCure Medical's stronger consensus rating and higher probable upside, research analysts plainly believe IceCure Medical is more favorable than HeartSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than IceCure Medical. HeartSciences is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	1.64	-$15.06M	-$8.52	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

HeartSciences has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
HeartSciences	N/A	-816.90%	-181.97%

Summary

HeartSciences beats IceCure Medical on 8 of the 15 factors compared between the two stocks.

How does IceCure Medical compare to Femasys?

IceCure Medical (NASDAQ:ICCM) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

IceCure Medical has a net margin of -427.67% compared to Femasys' net margin of -534.36%. IceCure Medical's return on equity of -174.26% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Femasys	-534.36%	-225.97%	-74.68%

IceCure Medical has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	1.64	-$15.06M	-$8.52	N/A
Femasys	$2.29M	7.90	-$18.63M	-$3.53	N/A

0.6% of IceCure Medical shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 2.4% of IceCure Medical shares are owned by insiders. Comparatively, 7.8% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, IceCure Medical had 2 more articles in the media than Femasys. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Femasys. Femasys' average media sentiment score of 1.82 beat IceCure Medical's score of 0.91 indicating that Femasys is being referred to more favorably in the news media.

Company	Overall Sentiment
IceCure Medical	Positive
Femasys	Very Positive

IceCure Medical presently has a consensus price target of $52.50, indicating a potential upside of 3,150.77%. Femasys has a consensus price target of $50.00, indicating a potential upside of 2,214.81%. Given IceCure Medical's higher probable upside, research analysts clearly believe IceCure Medical is more favorable than Femasys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

IceCure Medical has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Femasys has a beta of -2.07, suggesting that its stock price is 307% less volatile than the broader market.

Summary

IceCure Medical beats Femasys on 8 of the 15 factors compared between the two stocks.

How does IceCure Medical compare to Lifeward?

IceCure Medical (NASDAQ:ICCM) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, IceCure Medical had 2 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Lifeward. IceCure Medical's average media sentiment score of 0.91 equaled Lifeward'saverage media sentiment score.

Company	Overall Sentiment
IceCure Medical	Positive
Lifeward	Positive

IceCure Medical has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	1.64	-$15.06M	-$8.52	N/A
Lifeward	$22.03M	0.86	-$19.91M	-$16.82	N/A

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lifeward has a net margin of -141.28% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Lifeward	-141.28%	-235.86%	-81.72%

IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

IceCure Medical presently has a consensus target price of $52.50, suggesting a potential upside of 3,150.77%. Lifeward has a consensus target price of $10.00, suggesting a potential upside of 49.28%. Given IceCure Medical's higher probable upside, research analysts clearly believe IceCure Medical is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

IceCure Medical beats Lifeward on 10 of the 15 factors compared between the two stocks.

How does IceCure Medical compare to Modular Medical?

Modular Medical (NASDAQ:MODD) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

IceCure Medical has higher revenue and earnings than Modular Medical. Modular Medical is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Modular Medical	N/A	N/A	-$28.24M	-$8.69	N/A
IceCure Medical	$3.38M	1.64	-$15.06M	-$8.52	N/A

IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 3,150.77%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Modular Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Modular Medical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Modular Medical has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Modular Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Modular Medical	N/A	-292.14%	-222.79%
IceCure Medical	-427.67%	-174.26%	-112.58%

Modular Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 7.1% of Modular Medical shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, IceCure Medical had 2 more articles in the media than Modular Medical. MarketBeat recorded 3 mentions for IceCure Medical and 1 mentions for Modular Medical. Modular Medical's average media sentiment score of 1.82 beat IceCure Medical's score of 0.91 indicating that Modular Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Modular Medical	Very Positive
IceCure Medical	Positive

Summary

IceCure Medical beats Modular Medical on 10 of the 14 factors compared between the two stocks.

Get IceCure Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCM vs. The Competition

Export

Metric	IceCure Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.45M	$5.51B	$7.30B	$13.05B
Dividend Yield	N/A	1.79%	2.52%	14.40%
P/E Ratio	-0.19	24.95	273.69	25.69
Price / Sales	1.64	68.58	658.91	106.69
Price / Cash	N/A	32.86	79.75	52.21
Price / Book	0.43	5.68	10.46	6.29
Net Income	-$15.06M	$149.51M	$3.50B	$360.55M
7 Day Performance	-6.65%	-1.99%	-1.40%	-1.59%
1 Month Performance	-29.17%	-4.56%	-4.71%	-3.13%
1 Year Performance	-94.52%	4.59%	11.04%	2.88%

IceCure Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCM IceCure Medical	3.3716 of 5 stars	$1.62 +1.6%	$52.50 +3,150.8%	-94.7%	$5.45M	$3.38M	N/A	66	News Coverage Gap Up High Trading Volume
BEAT HeartBeam	2.5371 of 5 stars	$0.43 +0.6%	$4.00 +822.3%	-77.8%	$24.44M	N/A	N/A	1,700	News Coverage Analyst Forecast
HSCS HeartSciences	3.1544 of 5 stars	$4.61 -1.5%	$8.00 +73.5%	+20.1%	$22.13M	N/A	N/A	14
FEMY Femasys	3.2188 of 5 stars	$2.56 +1.2%	$50.00 +1,853.1%	-69.4%	$21.45M	$2.29M	N/A	54	Positive News Gap Up
LFWD Lifeward	2.5831 of 5 stars	$7.07 +1.1%	$10.00 +41.4%	-21.6%	$20.02M	$22.03M	N/A	81

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCM) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IceCure Medical (ICCM) Competitors

ICCM vs. BEAT, HSCS, FEMY, LFWD, and MODD

How does IceCure Medical compare to HeartBeam?

Summary

How does IceCure Medical compare to HeartSciences?

Summary

How does IceCure Medical compare to Femasys?

Summary

How does IceCure Medical compare to Lifeward?

Summary

How does IceCure Medical compare to Modular Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IceCure Medical (ICCM) Competitors

ICCM vs. BEAT, HSCS, FEMY, LFWD, and MODD

How does IceCure Medical compare to HeartBeam?

Do institutionals & insiders believe in BEAT or ICCM?

Does the media refer more to BEAT or ICCM?

Which has more risk and volatility, BEAT or ICCM?

Do analysts rate BEAT or ICCM?

Is BEAT or ICCM more profitable?

Which has preferable valuation & earnings, BEAT or ICCM?

Summary

How does IceCure Medical compare to HeartSciences?

Does the media prefer ICCM or HSCS?

Which has more risk & volatility, ICCM or HSCS?

Do institutionals and insiders hold more shares of ICCM or HSCS?

Do analysts rate ICCM or HSCS?

Which has higher valuation & earnings, ICCM or HSCS?

Is ICCM or HSCS more profitable?

Summary

How does IceCure Medical compare to Femasys?

Is ICCM or FEMY more profitable?

Which has preferable valuation and earnings, ICCM or FEMY?

Do institutionals & insiders believe in ICCM or FEMY?

Does the media prefer ICCM or FEMY?

Do analysts prefer ICCM or FEMY?

Which has more risk & volatility, ICCM or FEMY?

Summary

How does IceCure Medical compare to Lifeward?

Does the media refer more to ICCM or LFWD?

Which has preferable earnings and valuation, ICCM or LFWD?

Do institutionals and insiders believe in ICCM or LFWD?

Is ICCM or LFWD more profitable?

Which has more volatility and risk, ICCM or LFWD?

Do analysts rate ICCM or LFWD?

Summary

How does IceCure Medical compare to Modular Medical?

Which has preferable earnings and valuation, MODD or ICCM?

Do analysts recommend MODD or ICCM?

Is MODD or ICCM more profitable?

Which has more volatility & risk, MODD or ICCM?

Do institutionals & insiders hold more shares of MODD or ICCM?

Does the media favor MODD or ICCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCM vs. The Competition

IceCure Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools